

Curriculum Vitae

Personal information **Teun van Gelder**

Work experience

since Dec 2019 : Professor in Clinical Pharmacology, especially Drug Discovery & Development, Leiden University Medical Center, Leiden, The Netherlands

2010 -Dec 2019: Professor in Clinical Pharmacology, Erasmus Medical Center - Rotterdam - The Netherlands

Education and training

- 2002-2003 University Medical Center Nijmegen- Clinical Pharmacology (Prof. Dr. P. Smits), Registration as internist-clinical pharmacologist (December 1, 2003 – ongoing)
- 1995-1996 University Hospital Rotterdam - Nephrology (Prof. Dr. W. Weimar). Registration as internist-nephrologist (April 16, 1996 – April 16, 2023)
- 1988-1993 University Hospital Rotterdam - Internal Medicine (Prof. Dr. M.A.D.H. Schalekamp). Registration as Internist (May 1, 1993 - ongoing)
- 1980 - Feb 20, 1987, Medicine, Erasmus University Rotterdam, Netherlands

Additional information

Publications

Citation report Web of Science

Web of Science (accessed April 11, 2024):

635 publications

H-index = 66

Number of citations : 16,305

Without self citations: 14,920

Average citations per item: 25,68

Number of first authorships: 80

Number of last authorships: 109

Number of publications with >100 citations: 36

Highly Cited Papers (as first or last author):

583 citations: Hesselink DA, Van Schaik RHN, Van der Heiden IP, Van der Werf M, Smak Gregoor PJH, Lindemans J, Weimar W, **Van Gelder T**. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharm Ther 2003;74:245-254.

448 citations: **Van Gelder T**, Hilbrands LB, Vanrenterghem Y, Weimar W, De Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. *Transplantation* 1999;68:261-266.

265 citations: **Van Gelder T**, Klupp J, Barten MB, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. *Ther Drug Monitor* 2001;23:119-128.

234 citations: **van Gelder T**, Tedesco Silva H, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, le Meur Y, Oellerich M, Holt DW, Tönshoff B, Keown P, Campbell S, Mamelok RM. Comparing Mycophenolate Mofetil Regimens for De Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled (FDCC) Trial. *Transplantation*. 2008;86:1043-51

Top 3 highest impact factor as first or last author with name of the journal:

Van Hest RM, Mathôt RAA, Pescovitz MD, Gordon R, Mamelok RD, **Van Gelder T**. Explaining variability in mycophenolic acid (MPA) exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of MPA in renal transplant recipients. *J Am Soc Nephrol* 2006 Mar;17(3):871-80. Impact factor JASN = 13,6

van Gelder T, van Schaik RH, Hesselink DA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. *Nat Rev Nephrol*. 2014 Dec;10(12):725-731. Impact factor = 41,5

van Gelder T. How cyclosporine reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not. *Kidney Int*. 2021 Dec;100(6):1185-1189. Impact factor = 19,6

Your 5 most influential publications, including the number of citations

- List your 5 most influential publications, including the number of citations and the reasons why you have chosen these publications.
- **Van Gelder T**, Klupp J, Barten MB, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. *Ther Drug Monitor* 2001;23:119-128. **Motivation:** This drug-drug interaction study in rats showed for the first time that cyclosporine has a clinically significant interaction with mycophenolic acid pharmacokinetics. Although this was “only” a rat experiment, this paper now has over 265 citations!
- Burlingham WJ, Grailer AP, Heisey DM, Claas FHH, Norman D, Mohanakumar T, Brennan DC, Fijter de H, **Van Gelder T**, Pirsch JD, Sollinger HW, Bean MA. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. *N Engl J Med* 1998;339:1657-1664. **Motivation:** My only NEJM paper, but with a highly relevant message for clinical practice. Collaboration between US and Netherlands, including Leiden (Hans de Fijter and Frans Claas). Citations: 200

- van Leeuwen RW, **van Gelder T**, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. *Lancet Oncol*. 2014 Jul;15(8):e315-26. **Motivation:** Wonderful review paper on clinically relevant drug-drug interactions, in high ranked journal. Citations: 194
- Borra LC, Roodnat JJ, Kal JA, Mathot RA, Weimar W, **van Gelder T**. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. *Nephrol Dial Transplant*. 2010 Aug;25(8):2757-63. **Motivation:** This started as a student project, where we showed for the first time that the within-patient variability in tacrolimus levels is a risk factor for poor long-term outcome after kidney transplantation. Following our paper several groups repeated the analysis on their datasets and confirmed our findings. Citations: 193.
- Brunet M, **van Gelder T**, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Ther Drug Monit*. 2019 Jun;41(3):261-307. **Motivation:** Highly cited consensus paper on TDM of tacrolimus. Tacrolimus currently is, and will likely remain so for the next 20 years, the most important immunosuppressive drug to prevent rejection after solid organ transplantation. Citations: 353 (in less than 5 years time!).

Projects

Brief summary of research over the last five years (max 200 words)

I was trained in internal medicine, nephrology and clinical pharmacology. In 1991 I started my research on immunosuppressive drugs in the field of kidney and heart transplantation, and I completed my thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. After finishing my thesis I continued to work as a nephrologist, and my research focused on clinical pharmacology and therapeutic drug monitoring, both within the solid organ transplant field, but gradually also beyond transplant (oncology, psychiatry, dermatology). In December 2019 I accepted a new position in Leiden University Medical Center (LUMC), where I was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development.

Memberships

Local, National and International Activities and Responsibilities

Board memberships national :

- 2009 - 2015 Secretary of Dutch Transplantation Society
- 2011- 2017 Chairman of Dutch Society for Clinical Pharmacology and Biopharmacy
- 2003 - now Board member Clin Pharm of Dutch Society for Internal Medicine

Board memberships international :

- 2014 - present Council member Eur Ass for Clin Pharmacology & Therapeutics (EACPT)
- 2015 - 2017 President-Elect IATDMCT
- 2017- 2019 President IATDMCT
- 2019 -2021 Past- President IATDMCT

Editorial Boards:

- 1998 - present Reviewer, Transplant International
- 2003 - present Editorial Board - Therapeutic Drug Monitoring
- 2006 - present Editorial Board - Reviews on Clinical Transplantation
- 2007 - 2010 Editorial Board - Clinical Chemistry
- 2008 - present Editorial Board - Transplantation
- 2009 - present Editorial Board - Current Opinion in Organ Transplantation
- 2009 - present Editorial Board - Pharmacological Research
- 2010 - present Editorial Board - Clinical Pharmacokinetics
- 2010 -present Editorial Board - Clinical Pharmacology & Therapeutics
- 2014 -present Associate Editor - American Journal of Transplantation

Other Relevant Information

Brief summary of teaching over the last five years

After my arrival in Leiden I have successfully applied for the license to train residents in internal medicine for the differentiation clinical pharmacology. When this was obtained (2020) the programs for internal medicine, for hospital pharmacists and for research fellows were merged into one training program for all disciplines, allowing for a multidisciplinary curriculum. I am also involved in teaching medical and pharmacy students, either in separate groups, but also in an inter-disciplinary setting. It is nice to see that the you tube movies of the series "The medicine of the week" are also used in Leiden.